{"id":"https://openalex.org/W2802542587","doi":"https://doi.org/10.1158/1535-7163.mct-17-0848","title":"ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNF\u03b1-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth","display_name":"ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNF\u03b1-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth","alternate_titles":[],"publication_year":2018,"publication_date":"2018-07-01","ids":{"openalex":"https://openalex.org/W2802542587","doi":"https://doi.org/10.1158/1535-7163.mct-17-0848","mag":"2802542587","pmid":"https://pubmed.ncbi.nlm.nih.gov/29695633"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-17-0848","doi":"https://doi.org/10.1158/1535-7163.mct-17-0848","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-17-0848","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2802542587"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018819088","display_name":"George A. Ward","orcid":"https://orcid.org/0000-0001-9960-3896","observed_orcids":["https://orcid.org/0000-0001-9960-3896"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"George A. Ward","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041883762","display_name":"Edward J. Lewis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Edward J. Lewis","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057939832","display_name":"Jong Sook Ahn","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jong Sook Ahn","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101708420","display_name":"Christopher N. Johnson","orcid":"https://orcid.org/0000-0001-8618-9729","observed_orcids":["https://orcid.org/0000-0001-8618-9729"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christopher N. Johnson","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050224107","display_name":"John F. Lyons","orcid":"https://orcid.org/0009-0002-7080-7937","observed_orcids":["https://orcid.org/0009-0002-7080-7937"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John F. Lyons","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101901501","display_name":"Vanessa Martins","orcid":"https://orcid.org/0000-0003-2127-8338","observed_orcids":["https://orcid.org/0000-0003-2127-8338"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Vanessa Martins","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015763764","display_name":"Joanne M. Munck","orcid":"https://orcid.org/0000-0001-9389-4469","observed_orcids":["https://orcid.org/0000-0001-9389-4469"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joanne M. Munck","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053080479","display_name":"Sharna J. Rich","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sharna J. Rich","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004653800","display_name":"Tomoko Smyth","orcid":"https://orcid.org/0009-0004-5796-4377","observed_orcids":["https://orcid.org/0009-0004-5796-4377"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tomoko Smyth","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113528228","display_name":"Neil T. Thompson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Neil T. Thompson","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051132250","display_name":"Pamela A. Williams","orcid":"https://orcid.org/0000-0002-1257-2351","observed_orcids":["https://orcid.org/0000-0002-1257-2351"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pamela A. Williams","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043419424","display_name":"Nicola E. Wilsher","orcid":"https://orcid.org/0000-0001-6638-9715","observed_orcids":["https://orcid.org/0000-0001-6638-9715"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nicola E. Wilsher","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048676505","display_name":"Nicola G. Wallis","orcid":"https://orcid.org/0000-0001-7801-7185","observed_orcids":["https://orcid.org/0000-0001-7801-7185"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nicola G. Wallis","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003211614","display_name":"Gianni Chessari","orcid":"https://orcid.org/0000-0002-8151-7778","observed_orcids":["https://orcid.org/0000-0002-8151-7778"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gianni Chessari","raw_affiliation_strings":["Astex Pharmaceuticals, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Cambridge, United Kingdom","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.7123,"has_fulltext":false,"cited_by_count":88,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.9216978,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"17","issue":"7","first_page":"1381","last_page":"1391"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/inhibitor-of-apoptosis-proteins","display_name":"inhibitor of apoptosis proteins","score":0.9890000224113464},{"id":"https://openalex.org/keywords/bir3-domain","display_name":"BIR3 domain","score":0.6209999918937683},{"id":"https://openalex.org/keywords/smac","display_name":"Smac/DIABLO","score":0.47999998927116394},{"id":"https://openalex.org/keywords/non-canonical-nf-kappab-signaling","display_name":"non-canonical NF-\u03baB signaling","score":0.9599999785423279},{"id":"https://openalex.org/keywords/caspase-9","display_name":"caspase-9","score":0.828000009059906},{"id":"https://openalex.org/keywords/proteasomal-degradation","display_name":"proteasomal degradation","score":0.7400000095367432},{"id":"https://openalex.org/keywords/breast-cancer-xenografts","display_name":"breast cancer xenografts","score":0.828000009059906},{"id":"https://openalex.org/keywords/melanoma-xenografts","display_name":"melanoma xenografts","score":0.9950000047683716},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.7639999985694885},{"id":"https://openalex.org/keywords/fragment-based-drug-discovery","display_name":"fragment-based drug discovery","score":0.8830000162124634}],"concepts":[{"id":"https://openalex.org/C33195913","wikidata":"https://www.wikidata.org/wiki/Q20970121","display_name":"XIAP","level":5,"score":0.9759763479232788},{"id":"https://openalex.org/C2777408456","wikidata":"https://www.wikidata.org/wiki/Q174299","display_name":"Inhibitor of apoptosis","level":4,"score":0.8264216184616089},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.6531420350074768},{"id":"https://openalex.org/C124790011","wikidata":"https://www.wikidata.org/wiki/Q2069797","display_name":"Peptidomimetic","level":3,"score":0.6312593817710876},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.627926230430603},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.5651407837867737},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4894057810306549},{"id":"https://openalex.org/C2775975398","wikidata":"https://www.wikidata.org/wiki/Q906904","display_name":"Survivin","level":3,"score":0.4641749858856201},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4414568841457367},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.43331417441368103},{"id":"https://openalex.org/C2777383412","wikidata":"https://www.wikidata.org/wiki/Q4770891","display_name":"Antagonism","level":3,"score":0.4328809976577759},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.43061962723731995},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.42286115884780884},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3693486452102661},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.3414459228515625},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3074658215045929},{"id":"https://openalex.org/C98424977","wikidata":"https://www.wikidata.org/wiki/Q25805","display_name":"Caspase","level":4,"score":0.1956617534160614},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.14923521876335144},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C2779281246","wikidata":"https://www.wikidata.org/wiki/Q172847","display_name":"Peptide","level":2,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D018716","descriptor_name":"Molecular Mimicry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051034","descriptor_name":"Inhibitor of Apoptosis Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051034","descriptor_name":"Inhibitor of Apoptosis Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051034","descriptor_name":"Inhibitor of Apoptosis Proteins","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051636","descriptor_name":"X-Linked Inhibitor of Apoptosis Protein","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051636","descriptor_name":"X-Linked Inhibitor of Apoptosis Protein","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051636","descriptor_name":"X-Linked Inhibitor of Apoptosis Protein","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D054730","descriptor_name":"Protein Interaction Domains and Motifs","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-17-0848","doi":"https://doi.org/10.1158/1535-7163.mct-17-0848","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-17-0848","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:29695633","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29695633","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320314605","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":49,"referenced_works":["https://openalex.org/W8868882","https://openalex.org/W1011422075","https://openalex.org/W1203651314","https://openalex.org/W1599411566","https://openalex.org/W1970010835","https://openalex.org/W1973462203","https://openalex.org/W1975506525","https://openalex.org/W1978064993","https://openalex.org/W1989157196","https://openalex.org/W1993262664","https://openalex.org/W1998918148","https://openalex.org/W2002645985","https://openalex.org/W2003926188","https://openalex.org/W2005572311","https://openalex.org/W2008181517","https://openalex.org/W2008961838","https://openalex.org/W2023056845","https://openalex.org/W2032585021","https://openalex.org/W2033914606","https://openalex.org/W2042409437","https://openalex.org/W2043398720","https://openalex.org/W2063690467","https://openalex.org/W2064235684","https://openalex.org/W2064299413","https://openalex.org/W2069800916","https://openalex.org/W2078361177","https://openalex.org/W2091269867","https://openalex.org/W2091846487","https://openalex.org/W2099624217","https://openalex.org/W2102403951","https://openalex.org/W2114727688","https://openalex.org/W2115697154","https://openalex.org/W2115785123","https://openalex.org/W2116609506","https://openalex.org/W2117692326","https://openalex.org/W2123123035","https://openalex.org/W2125715557","https://openalex.org/W2136748425","https://openalex.org/W2139641636","https://openalex.org/W2146226667","https://openalex.org/W2147744317","https://openalex.org/W2156299397","https://openalex.org/W2158664527","https://openalex.org/W2167490100","https://openalex.org/W2173116224","https://openalex.org/W2288109457","https://openalex.org/W2562693435","https://openalex.org/W2613766095","https://openalex.org/W2727121935"],"related_works":["https://openalex.org/W4235391640","https://openalex.org/W3124832652","https://openalex.org/W3083431193","https://openalex.org/W2885499773","https://openalex.org/W1990142651","https://openalex.org/W3109866703","https://openalex.org/W3094959202","https://openalex.org/W2951763199","https://openalex.org/W2502629403","https://openalex.org/W2069800916"],"abstract_inverted_index":{"Because":[0],"of":[1,7,10,22,60,71,97,112,127,135,140,154,194],"their":[2],"roles":[3],"in":[4,33,84,86,132,156,161,165,181],"the":[5,26,93],"evasion":[6],"apoptosis,":[8],"inhibitor":[9],"apoptosis":[11,155],"proteins":[12,24],"(IAP)":[13],"are":[14,206],"considered":[15],"attractive":[16],"targets":[17],"for":[18],"anticancer":[19],"therapy.":[20],"Antagonists":[21],"these":[23],"have":[25,45],"potential":[27],"to":[28,92,151],"switch":[29],"prosurvival":[30],"signaling":[31],"pathways":[32],"cancer":[34,158],"cells":[35,106],"toward":[36],"cell":[37,159],"death.":[38],"Various":[39],"SMAC-peptidomimetics":[40],"with":[41,102,148],"inherent":[42],"cIAP":[43],"selectivity":[44],"been":[46],"tested":[47,180],"clinically":[48],"and":[49,62,73,83,100,107,129,138,169,188,196],"demonstrated":[50,78,115,144],"minimal":[51],"single-agent":[52],"efficacy.":[53],"ASTX660":[54,76,149,176],"is":[55,177],"a":[56,182],"potent,":[57],"non-peptidomimetic":[58],"antagonist":[59],"cIAP1/2":[61,145,195,208],"XIAP,":[63],"discovered":[64],"using":[65],"fragment-based":[66],"drug":[67],"design.":[68],"The":[69,89],"antagonism":[70,111,193],"XIAP":[72,99,113,197],"cIAP1":[74,101,128],"by":[75,116],"was":[77,114],"on":[79],"purified":[80],"proteins,":[81],"cells,":[82],"vivo":[85],"xenograft":[87,108],"models.":[88],"compound":[90],"binds":[91],"isolated":[94],"BIR3":[95],"domains":[96],"both":[98],"nanomolar":[103],"potencies.":[104],"In":[105],"tissue,":[109],"direct":[110],"measuring":[117],"its":[118,192],"displacement":[119],"from":[120],"caspase-9":[121],"or":[122],"SMAC.":[123],"Compound-induced":[124],"proteasomal":[125],"degradation":[126],"2,":[130],"resulting":[131],"downstream":[133],"effects":[134],"NIK":[136],"stabilization":[137],"activation":[139],"noncanonical":[141],"NF-\u03baB":[142],"signaling,":[143],"antagonism.":[146],"Treatment":[147],"led":[150],"TNF\u03b1-dependent":[152],"induction":[153],"various":[157],"lines":[160],"vitro,":[162],"whereas":[163],"dosing":[164],"mice":[166],"bearing":[167],"breast":[168],"melanoma":[170],"tumor":[171,174],"xenografts":[172],"inhibited":[173],"growth.":[175],"currently":[178],"being":[179],"phase":[183],"I\u2013II":[184],"clinical":[185],"trial":[186],"(NCT02503423),":[187],"we":[189],"propose":[190],"that":[191,205],"may":[198],"offer":[199],"improved":[200],"efficacy":[201],"over":[202],"first-generation":[203],"antagonists":[204],"more":[207],"selective.":[209],"Mol":[210],"Cancer":[211],"Ther;":[212],"17(7);":[213],"1381\u201391.":[214],"\u00a92018":[215],"AACR.":[216]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2802542587","counts_by_year":[{"year":2026,"cited_by_count":11},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":17},{"year":2020,"cited_by_count":12},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":2}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2018-05-17T00:00:00"}
